Frequent but nonrandom expression of myeloid markers on de novo childhood acute lymphoblastic leukemia

Experimental and Molecular Pathology

Volumn 83, Issue 1, 2007, Pages 138-141

  Abdelhaleem, Mohamed ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

CD13; CD15; CD33; Childhood acute lymphoblastic leukemia; Myeloid markers

Indexed keywords

AF4 PROTEIN; CD15 ANTIGEN; CD33 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; MICROSOMAL AMINOPEPTIDASE; MIXED LINEAGE LEUKEMIA PROTEIN; TRANSCRIPTION FACTOR E2A; TRANSCRIPTION FACTOR ETV6; TRANSCRIPTION FACTOR PBX1; TRANSCRIPTION FACTOR RUNX1; TUMOR MARKER; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ARTICLE; B LYMPHOCYTE; CELL LINEAGE; CHILD; CHILDHOOD LEUKEMIA; CONTROLLED STUDY; DISEASE MARKER; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE;

ANTIGENS, CD; ANTIGENS, CD13; ANTIGENS, CD15; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; CELL DIFFERENTIATION; CHILD; CORE BINDING FACTOR ALPHA 2 SUBUNIT; HOMEODOMAIN PROTEINS; HUMANS; LEUKEMIA, B-CELL, ACUTE; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; MYELOID CELLS; ONCOGENE PROTEINS, FUSION; TUMOR MARKERS, BIOLOGICAL;

EID: 34249800923     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2007.02.004     Document Type: Article

References (16)

1. Baruchel A., Cayuela J.M., Ballerini P., Landman-Parker J., Cezard V., Firat H., Haddad E., Auclerc M.F., Valensi F., Cayre Y.E., Macintyre E.A., and Sigaux F. The majority of myeloid-antigen-positive (My+) childhood B-cell precursor acute lymphoblastic leukaemias express TEL-AML1 fusion transcripts. Br. J. Haematol. 99 (1997) 101-106
2. Behm F.G. Immunophenotyping. In: Pui C.-H. (Ed). Childhood Leukemias. 2nd edition (2006), Cambridge Univ. Press
3. Borkhardt A., Cazzaniga G., Viehmann S., Valsecchi M.G., Ludwig W.D., Burci L., Mangioni S., Schrappe M., Riehm H., Lampert F., Basso G., Masera G., Harbott J., and Biondi A. Incidence and clinical relevance of TEL/AML1 fusion genes in children with acute lymphoblastic leukemia enrolled in the German and Italian multicenter therapy trials. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Munster Study Group. Blood 90 (1997) 571-577
4. Borowitz M.J., Guenther K.L., Shults K.E., and Stelzer G.T. Immunophenotyping of acute leukemia by flow cytometric analysis. Use of CD45 and right-angle light scatter to gate on leukemic blasts in three-color analysis. Am. J. Clin. Pathol. 100 (1993) 534-540
5. Borowitz M.J., Hunger S.P., Carroll A.J., Shuster J.J., Pullen D.J., Steuber C.P., and Cleary M.L. Predictability of the t(1;19)(q23;p13) from surface antigen phenotype:implications for screening cases of childhood acute lymphoblastic leukemia for molecular analysis: a Pediatric Oncology Group Study. Blood 82 (1993) 1086-1091
6. Borowitz M.J., Rubnitz J., Nash M., Pullen D.J., and Camitta B. Surface antigen phenotype can predict TEL-AML1 rearrangement in childhood B-precursor ALL: a Pediatric Oncology Group study. Leukemia 12 (1998) 1764-1770
7. Cimino G., Elia L., Mancini M., Annino L., Anaclerico B., Fazi P., Vitale A., Specchia G., Di Raimondo F., Recchia A., Cuneo A., Mecucci C., Pane F., Saglio G., Foa R., and Mandelli F. Clinico-biologic features and treatment outcome of adult pro-B-ALL patients enrolled in the GIMEMA 0496 study: absence of the ALL1/AF4 and of the BCR/ABL fusion genes correlates with a significantly better clinical outcome. Blood 102 (2003) 2014-2020
8. Cox C.V., and Blair A. A primitive cell origin for B-cell precursor ALL. Stem Cell Rev. 1 (2005) 189-196
9. Foa R., Vitale A., Mancini M., Cuneo A., Mecucci C., Elia L., Lombardo R., Saglio G., Torelli G., Annino L., Specchia G., Damasio E., Recchia A., Di Raimondo F., Morra E., Volpe E., Tafuri A., Fazi P., Hunger S.P., and Mandelli F. E2A-PBX1 fusion in adult acute lymphoblastic leukaemia: biological and clinical features. Br. J. Haematol. 120 (2003) 484-487
10. Hotfilder M., Rottgers S., Rosemann A., Jurgens H., Harbott J., and Vormoor J. Immature CD34+CD19- progenitor/stem cells in TEL/AML1-positive acute lymphoblastic leukemia are genetically and functionally normal. Blood 100 (2002) 640-646
11. Hotfilder M., Rottgers S., Rosemann A., Schrauder A., Schrappe M., Pieters R., Jurgens H., Harbott J., and Vormoor J. Leukemic stem cells in childhood high-risk ALL/t(9;22) and t(4;11) are present in primitive lymphoid-restricted CD34+CD19- cells. Cancer Res. 65 (2005) 1442-1449
12. Maynadie M., Campos L., Moskovtchenko P., Sabido O., Aho S., Lenormand B., Carli P.M., Guyotat D., Bene M.C., Faure G., and Geil T. Heterogenous expression of CD15 in acute lymphoblastic leukemia: a study of ten anti-CD15 monoclonal antibodies in 158 patients. Leuk. Lymphoma 25 (1997) 135-143
13. Niehues T., Kapaun P., Harms D.O., Burdach S., Kramm C., Korholz D., Janka-Schaub G., and Gobel U. A classification based on T cell selection-related phenotypes identifies a subgroup of childhood T-ALL with favorable outcome in the COALL studies. Leukemia 13 (1999) 614-617
14. Pui C.H., Frankel L.S., Carroll A.J., Raimondi S.C., Shuster J.J., Head D.R., Crist W.M., Land V.J., Pullen D.J., Steuber C.P., Behm F.G., and Borowitz M.J. Clinical characteristics and treatment outcome of childhood acute lymphoblastic leukemia with the t(4;11)(q21;q23): a collaborative study of 40 cases. Blood 77 (1991) 440-447
15. Pui C.H., Rubnitz J.E., Hancock M.L., Downing J.R., Raimondi S.C., Rivera G.K., Sandlund J.T., Ribeiro R.C., Head D.R., Relling M.V., Evans W.E., and Behm F.G. Reappraisal of the clinical and biologic significance of myeloid-associated antigen expression in childhood acute lymphoblastic leukemia. J. Clin. Oncol. 16 (1998) 3768-3773
16. Van Dongen J.J., Macintyre E.A., Gabert J.A., Delabesse E., Rossi V., Saglio G., Gottardi E., Rambaldi A., Dotti G., Griesinger F., Parreira A., Gameiro P., Diaz M.G., Malec M., Langerak A.W., San Miguel J.F., and Biondi A. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia 13 (1999) 1901-1928